Ramez Eskander News Today

Keytruda plus chemotherapy has been granted a priority review by the FDA to treat certain patients with endometrial cancer.

The Foundation for Women's Cancer (FWC) is pleased to host a Patient and Advocate Education Forum on​​ Friday, March 15, 2024, 10 a.m. – 4:30 p.m. PT, in San Diego, CA, at the San Diego Convention Center the day before the start of the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women's Cancer.

The Foundation for Women’s Cancer (FWC) is pleased to host a free Patient and Advocate Education Forum on​​ Friday, March 15, 2024, 10 a.m. – 4:30 p.m.

Closing their conversation, Ramez Eskander, MD, and Krishnansu Tewari, MD, share how they envision the future treatment landscape for patients with advanced endometrial cancer.

Ramez Eskander, MD, presents the profile of a 64-year-old postmenopausal woman diagnosed with recurrent endometrial carcinoma for discussion.

Ramez Eskander, MD, and Krishnansu Tewari, MD, provide an overview of endometrial cancer, including prevalence, staging criteria, and molecular profiling.

Experts on endometrial cancer review the NRG-GY018 and RUBY clinical trials.

Christian Marth, MD, PhD, and Bradley J. Monk, MD, FACS, FACOG, discuss data from the NRG GY018 and RUBY trials regarding the use of immunotherapies for the treatment of endometrial cancer.

Improvements in progression-free survival were seen in patients with advanced or recurrent endometrial carcinoma regardless of mismatch repair status.

KENILWORTH (NJ) (dpa-AFX) - Drug major Merck & Co. Inc. (MRK) announced Friday that KEYTRUDA plus chemotherapy met primary endpoint of progression-free survival or PFS as first-line therapy for